LAFAYETTE, Colo., Jan. 21 /PRNewswire/ -- Dharmacon, Inc., the world's leading supplier of innovative RNA and RNA interference (RNAi) research products, today announced that Genentech, Inc. has selected Dharmacon's advanced RNAi technology for use in its drug discovery and development research. Under an agreement between the two companies, Dharmacon will supply Genentech with a range of siRNA reagents including Dharmacon's Human Druggable Genome library, which focuses on those genes that are considered potential targets for therapeutics.
"We think it is fitting that Dharmacon, a pioneer in RNAi research, has been selected by Genentech, one of the world's leading biotechnology companies, to supply advanced siRNA products and technology for its drug discovery research programs," said Leland Foster, president and chief executive officer of the Biosciences group of Fisher Scientific International Inc. "We believe this agreement is further indication that Dharmacon's SMARTselection and SMARTpool technologies are a preferred gene-silencing platform for drug discovery research among leading pharmaceutical and biotechnology companies. Dharmacon's continued leadership in the RNAi field and the exceptional potency and specificity of our siRNA reagents make us the supplier of choice for researchers utilizing RNAi technology to accelerate drug discovery."
Further terms were not disclosed.
Dharmacon is the world's leading provider of reliable, high quality RNA oligonucleotides, small interfering RNA (siRNA) and related RNA-interference (RNAi) products and technologies. Using its core expertise in chemistry, biology, bioinformatics and production, Dharmacon has pioneered a custom siRNA design service that employs its proprietary technologies for maximizing the efficiency of gene silencing, a powerful and increasingly widely-used new technology based on siRNA. Dharmacon's proprietary SMARTselection(TM) and SMARTpool(R) technologies result in potent and specific gene-silencing agents that can accelerate a broad range of life-science research. Dharmacon's siGENOMETM siRNA, a comprehensive and flexible gene-silencing collection, offers guaranteed SMARTpool reagents and SMARTselection-designed siRNAs targeting all unique human mouse and rat genes in the NCBI RefSeq database. The company's ON-TARGET(TM) siRNA modifications further enhances silencing specificity, and its revolutionary new siSTABLE(TM) siRNA offers unparalleled stability and gene-silencing longevity. Founded in 1995 and based in Lafayette, Colo., Dharmacon is a subsidiary of Fisher Scientific International Inc. For more information, visit the company's website at http://www.dharmacon.com/.
Michael Deines Barbara Lindheim
Vice President, Sales and Marketing GendeLLindheim BioCom Partners
CONTACT: Michael Deine, Vice President, Sales and Marketing ofDharmacon, +1-303-604-9499; or media, Barbara Lindheim of GendeLLindheimBioCom Partners, +1-212-918-4650, for Dharmacon, Inc.